Mechanistic Insights into Cancer Immunotherapy and Immune-Related Adverse Events

Dear Colleagues,

With the rapid evolution of cancer immunotherapy, its role in clinical treatment has become increasingly prominent. Current research in cancer immunotherapy is dedicated to recognizing and treating immune-related adverse events (irAEs) without compromising the efficacy of cancer treatment. However, the pathophysiological mechanisms underlying irAEs are not fully understood, which limits the development of targeted therapies. irAEs associated with immunotherapy remain a complex and challenging field. For this Special Issue, we are particularly interested in papers that can translate basic scientific research into clinical applications. This includes but is not limited to:

• The molecular and cellular mechanisms of irAEs in cancer immunotherapy.
• The discovery and validation of predictive biomarkers and their application in early diagnosis and personalized treatment.
• The development and evaluation of evidence-based treatment methods for specific types of irAEs.
• Multidisciplinary research approaches to address technical and methodological limitations in irAEs research.

We invite researchers, clinicians, and scientists to submit original molecular research, reviews, and case reports on the mechanisms, diagnosis, treatment, and management strategies of cancer immunotherapy and its related irAEs. We anticipate that your contributions will provide new insights into the safety and efficacy of cancer immunotherapy.

Dr. Noha Abdel-Wahab
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cancer immunotherapy
• immune-related adverse events
• biomarker
• immune checkpoint inhibitor
• cancer progression